Loading
Life sciences · Journal article
Nuclear Medicine Communications · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
OBJECTIVE: To evaluate the role of liver and bone marrow organomics features derived from staging 18F-fluorodeoxyglucose (18F-FDG) PET/MRI in predicting pathological complete response (pCR) in breast cancer patients who underwent surgery after neoadjuvant therapy. METHODS: In this retrospective study, breast cancer patients who underwent pretreatment staging with 18F-FDG PET/MRI, received neoadjuvant therapy, and subsequently underwent surgery were included. Clinicopathological characteristics and systemic inflammatory markers were recorded. Organomics features were extracted from the liver and L4 vertebra bone marrow regions on 18F-FDG PET images using LIFEx software. Least Absolute Shrinkage and Selection Operator regression was applied for radiomics feature selection, and a radiomics score (Radscore) was generated. Logistic regression analyses were performed to identify predictors of pCR. The diagnostic performances of the Radscore, Clinical, and Clinical-Radscore Combined models were evaluated using receiver operating characteristic analysis. RESULTS: A total of 87 breast cancer patients were included, and pCR was observed in 33 patients (37.9%). In multivariable analysis, progesterone receptor status, human epidermal growth factor receptor 2 status, primary tumor size, and Radscore were identified as independent predictors of pCR. The Radscore yielded an area under the curve (AUC) of 0.722 [95% confidence interval (CI) = 0.625-0.819], whereas the Clinical and Clinical-Radscore Combined models achieved AUCs of 0.850 (95% CI = 0.765-0.934) and 0.904 (95% CI = 0.843-0.965), respectively. The Clinical-Radscore Combined Model demonstrated higher diagnostic performance than both the other models. CONCLUSION: Liver and bone marrow organomics features derived from staging 18F-FDG PET/MRI may provide valuable information for predicting pCR in breast cancer patients undergoing neoadjuvant therapy.